The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways

Li,Wang1; Rong,Qiu2; Zhaoyang,Zhang1; Zhijun,Han3; Chao,Yao2; Guojun,Hou1; Dai,Dai4; Wenfei,Jin3; Yuanjia,Tang1; Xiang,Yu1; Nan,Shen1,4,5

2020-06-01

10.4049/immunohorizons.2000008

ImmunoHorizons   影响因子和分区

2573-7732

Others

英语

其他

The American Association of Immunologists

人工提交

1.Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
2.Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200025, China.
3.Department of Biology, Southern University of Science and Technology, Shenzhen 518055, China.
4.China-Australia Centre for Personalized Immunology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; and.
5.Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China; nanshensibs@gmail.com.
6.Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229.

Li,Wang,Rong,Qiu,Zhaoyang,Zhang,et al. The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways[J]. ImmunoHorizons,2020,4(6):308-318.

Li,Wang.,Rong,Qiu.,Zhaoyang,Zhang.,Zhijun,Han.,Chao,Yao.,...&Nan,Shen.(2020).The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways.ImmunoHorizons,4(6),308-318.

Li,Wang,et al."The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways".ImmunoHorizons 4.6(2020):308-318.